share_log

藥明巨諾-B：截至二零二四年二月二十九日止月份之股份發行人的證券變動月報表

JW THERAP-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

香港交易所 ·  Mar 6 03:56
Summary by Moomoo AI
药明巨诺-B（02126.HK）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的資料。報告顯示，公司的法定/註冊股本維持不變，總額為50,000美元，每股面值0.00001美元，總股份數目為5,000,000,000股。在股份期權方面，根據不同激勵計劃，本月內有股份期權被行使，導致股份期權數目有所減少，但未有新股份發行。公司確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
药明巨诺-B（02126.HK）於2024年3月6日向香港交易及結算所有限公司提交了最新的證券變動月報表，涵蓋截至2024年2月29日的資料。報告顯示，公司的法定/註冊股本維持不變，總額為50,000美元，每股面值0.00001美元，總股份數目為5,000,000,000股。在股份期權方面，根據不同激勵計劃，本月內有股份期權被行使，導致股份期權數目有所減少，但未有新股份發行。公司確認，所有證券發行均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的要求。
Pharmaceutical Ming Jeno B (02126.HK) filed with Hong Kong Trading and Settlement Limited on March 6, 2024 with Hong Kong Trading and Settlement Limited, covering data for the year ending February 29, 2024. The report showed that the company's regulated/registered share capital remained unchanged, totaling $50,000, with a face value of $0.00001 per share, and the total number of shares was 5,000,000,000 shares. In terms of stock options, under different incentive schemes, share options were exercised during the month, resulting in a reduced number of share options, but no new shares were issued. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Pharmaceutical Ming Jeno B (02126.HK) filed with Hong Kong Trading and Settlement Limited on March 6, 2024 with Hong Kong Trading and Settlement Limited, covering data for the year ending February 29, 2024. The report showed that the company's regulated/registered share capital remained unchanged, totaling $50,000, with a face value of $0.00001 per share, and the total number of shares was 5,000,000,000 shares. In terms of stock options, under different incentive schemes, share options were exercised during the month, resulting in a reduced number of share options, but no new shares were issued. The Company confirms that all securities issuance has been approved by the Board of Directors and complies with the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more